Hypotensive Action of Melatonin in Patients with Arterial Hypertension

Login or register to view PDF.
Creative Commons Licence
 
Received date
15 May 2020
Accepted date
15 May 2020
Citation
European Cardiology Review 2020;15:e43.
DOI
https://doi.org/10.15420/ecr.2020.15.1.PO20
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Objective: To evaluate the efficacy and safety of melatonin therapy in hypertensive patients based on the assessment of daily blood pressure monitoring.

Materials and methods: 30 men with arterial hypertension aged from 27 to 58 years, mean age 45.5 ± 9.2 years, were included in the study. Daily ambulatory blood pressure monitoring with a portable BR-102 Plus blood pressure registrar (Schiller) was conducted on the first day of the study and on the next day after receiving a therapeutic dose of melatonin. Melatonin (Melaxen, Unipharm) was administered on the second day of the study, 3 mg once daily, 9 am–10 am. Average value of 24-hour, day-and night-time brachial systolic (SBP) and diastolic blood pressure (DBP) were assessed.

Results: Average 24-hour SBP and DBP values decreased after melatonin intake – from 124.6 ± 12.1 to 121.0 ± 10.2 mmHg (p<0.03), and 79.7 ± 8.8 to 77.3 ± 6.5 mmHg (p<0.03), respectively, as well as average day-time SBP and DBP values – from 128.2 ± 13.2 to 122.5 ± 9.9 mmHg (p<0.003) and 82.3 ± 9.7 to 78.5 ± 7.2 mmHg (p<0.006). Average night-time DBP and SBP values did not change (p>0.05). There were no side-effects observed after melatonin treatment.

Conclusion: A single administration of melatonin in a therapeutic dose causes a short-term reduction in blood pressure, predominantly due to the reduction of 24-hour and day-time systolic and diastolic blood pressure. Further studies are needed to prove the efficacy of melatonin in arterial hypertension treatment.